Bharat Immunological Biological Corporation Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Bharat Immunological & Biological Corporation Ltd is ₹ 17.33 as of 05 May 15:30 . The P/E Ratio of Bharat Immunological & Biological Corporation Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Bharat Immunological & Biological Corporation Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Bharat Immunological & Biological Corporation Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Bharat Immunological & Biological Corporation Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Bharat Immunological & Biological Corporation Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Bharat Immunological & Biological Corporation Ltd changed from 0 % to 0 % over 8 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 8 quarters. This represents a CAGR of -100.00% .

About Bharat Immunological & Biological Corporation Ltd

The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
BIBCOL was incorporated in 1989.
The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets. The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
BIBCL installed a plant of 100 mln units.
Commercial production of the OPV started from Jan'96. The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Bharat Immunological & Biological Corporation Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Bharat Immunological & Biological Corporation Ltd or Sanofi India Ltd?

Market cap of Bharat Immunological & Biological Corporation Ltd is 75 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Bharat Immunological & Biological Corporation Ltd and Sanofi India Ltd?

The stock performance of Bharat Immunological & Biological Corporation Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bharat Immunological & Biological Corporation Ltd and Sanofi India Ltd?

As of May 5, 2026, the Bharat Immunological & Biological Corporation Ltd stock price is INR ₹17.5. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Bharat Immunological & Biological Corporation Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Bharat Immunological & Biological Corporation Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.